Elenagen™, a novel DNA plasmid therapy that previously demonstrated high clinical benefit and low toxicity in cancer patients, has now shown significant promise in alleviating chronic pain ...

Neoadjuvant immunotherapy is associated with high rates of event-free survival in patients with resectable melanoma.

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Panelists discuss how subcutaneous (SubQ) and intravenous (IV) oncology therapies will continue to coexist, with ...

Q2 2025 Earnings Call Transcript July 16, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.77, ...

Improvements in rural cancer care in Kentucky could be imperiled by President Trump's tax and domestic policy bill.

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...

A stage-four cancer diagnosis once sounded like the end of the road – after all, there is no stage five. When Joe Biden’s ...

Alex the Great, a beloved therapy rabbit that brought comfort to arenas and other major venues across the U.S., has died. He ...

Study in Frontiers in Veterinary Science finds investigational plasmid Elenagen cut osteoarthritis pain by 50 % in dogs and ...

Cancer cells rapidly adapt to treatments, developing resistance that makes chemotherapy less effective. Researchers used an existing anti-inflammatory drug to disrupt cancer cells’ ability to adapt by ...

Harvard University faces a critical court hearing against the Trump administration over a $2 billion federal funding freeze ...